BiotechTube

N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Laparoscopic Surgery

Conditions

Laparoscopic Surgery

Trial Timeline

Oct 1, 2011 → Mar 1, 2012

NCT ID
NCT01436032

About N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo

N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo is a phase 3 stage product being developed by Alkermes for Laparoscopic Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT01436032. Target conditions include Laparoscopic Surgery.

What happened to similar drugs?

3 of 5 similar drugs in Laparoscopic Surgery were approved

Approved (3) Terminated (0) Active (2)
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
✅Rocuronium + RocuroniumMerckApproved
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅etoricoxib 120 mgMerckApproved
🔄placebo + valdecoxib + valdecoxibPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01436032Phase 3Terminated

Competing Products

7 competing products in Laparoscopic Surgery

See all competitors
ProductCompanyStageHype Score
Pudexacianinium chlorideAstellas PharmaPhase 2
35
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
Entereg + Entereg + placeboMerckPhase 2
35
Rocuronium + RocuroniumMerckApproved
43
Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
39
etoricoxib 120 mgMerckApproved
43
placebo + valdecoxib + valdecoxibPfizerPhase 3
40